NANO Nanobiotix SA

Nanobiotix to Present at Upcoming Investor Conferences in March

Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event.

Leerink Partners Global Biopharma Conference

Date: Wednesday, March 13, 2024

Time: 8:40 AM EST / 1:40 PM CET

Location: Miami, FL

Presenter: Laurent Levy, co-founder of Nanobiotix and chairman of the executive board

Guggenheim Healthy Altitudes Summit

Date: Wednesday, March 13, 2024

Time: 8:15 AM MST / 4:15 PM CET

Location: Telluride, CO

Presenter: Bart Van Rhijn, chief financial officer of Nanobiotix

The fireside chats will be webcast live from the of the Investors section of the Company’s website. Replays of the webcasts will be available following the events.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix 


Communications Department


Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department

Craig West

SVP, Investor Relations

+1 (617) 583-0211

 
Media Relations 


FR – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

Global – LifeSci Advisors

Kevin Gardner

+1 (617) 283-2856

 

Attachment



EN
06/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financi...

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and data ...

 PRESS RELEASE

NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FIN...

NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR L’ANNÉE 2023 L’accord de licence globale de co-développement et de commercialisation avec Janssen Pharmaceutica NV (« Janssen ») étend le potentiel du radioenhancer NBTXR3 à l’échelle internationale.La survie prolongée observée dans l’Étude 102 soutient la conception de l’essai pivot NANORAY-312 dans le cancer de la tête et du cou. Les premiers signes d’efficacité et le profil de sécurité favorable renforcent le potentiel de NBTXR3 dans le cancer du pancréas. La dose recommandée pour la Phase 2 a été détermin...

 PRESS RELEASE

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational a...

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, ...

 PRESS RELEASE

NANOBIOTIX publiera ses résultats financiers et opérationnels de l'exe...

NANOBIOTIX publiera ses résultats financiers et opérationnels de l'exercice 2023 le 24 avril 2024 Conférence téléphonique et diffusion en direct sur Internet le jeudi 25 avril 2024 à 14 h 00 CEST / 8 h 00 EDT PARIS et CAMBRIDGE, Mass., 17 avr. 2024 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la physique pour élargir les possibilités de traitement des patients atteints de cancer, annonce aujourd’hui qu’elle publiera, le mercredi 24 avril 2024, a...

 PRESS RELEASE

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 10, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights, exercisable2March 31, 202447,133,32848,899,41048,877,292 According to the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch